Vistin Pharma (VISTN) Stock Overview
Through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
VISTN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Vistin Pharma ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 21.60 |
| 52 Week High | NOK 27.30 |
| 52 Week Low | NOK 19.40 |
| Beta | 0.64 |
| 1 Month Change | 2.86% |
| 3 Month Change | 5.37% |
| 1 Year Change | -9.62% |
| 3 Year Change | 19.34% |
| 5 Year Change | -18.49% |
| Change since IPO | 14.29% |
Recent News & Updates
Recent updates
Vistin Pharma's (OB:VISTN) Shareholders Will Receive A Bigger Dividend Than Last Year
May 23
We Think Shareholders Will Probably Be Generous With Vistin Pharma ASA's (OB:VISTN) CEO Compensation
May 16Vistin Pharma (OB:VISTN) Is Paying Out A Larger Dividend Than Last Year
Apr 30Vistin Pharma's (OB:VISTN) Upcoming Dividend Will Be Larger Than Last Year's
Feb 16Here's Why Vistin Pharma (OB:VISTN) Has Caught The Eye Of Investors
Sep 18Would Vistin Pharma (OB:VISTN) Be Better Off With Less Debt?
Feb 23A Look At The Fair Value Of Vistin Pharma ASA (OB:VISTN)
Sep 09Robust Earnings May Not Tell The Whole Story For Vistin Pharma (OB:VISTN)
Aug 25Investors In Vistin Pharma ASA (OB:VISTN) Should Consider This, First
Mar 15We're Keeping An Eye On Vistin Pharma's (OB:VISTN) Cash Burn Rate
Feb 20
Could The Vistin Pharma ASA (OB:VISTN) Ownership Structure Tell Us Something Useful?
Jan 29The Vistin Pharma (OB:VISTN) Share Price Is Up 119% And Shareholders Are Boasting About It
Jan 08Have Insiders Been Selling Vistin Pharma ASA (OB:VISTN) Shares?
Dec 16Is Vistin Pharma ASA (OB:VISTIN) At Risk Of Cutting Its Dividend?
Nov 26Shareholder Returns
| VISTN | NO Pharmaceuticals | NO Market | |
|---|---|---|---|
| 7D | 0% | -3.2% | 1.9% |
| 1Y | -9.6% | -0.6% | 24.0% |
Return vs Industry: VISTN underperformed the Norwegian Pharmaceuticals industry which returned -0.6% over the past year.
Return vs Market: VISTN underperformed the Norwegian Market which returned 24% over the past year.
Price Volatility
| VISTN volatility | |
|---|---|
| VISTN Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in NO Market | 10.1% |
| 10% least volatile stocks in NO Market | 2.9% |
Stable Share Price: VISTN has not had significant price volatility in the past 3 months compared to the Norwegian market.
Volatility Over Time: VISTN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1969 | 73 | Magnus Tolleshaug | www.vistin.com |
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is based in Oslo, Norway.
Vistin Pharma ASA Fundamentals Summary
| VISTN fundamental statistics | |
|---|---|
| Market cap | NOK 957.84m |
| Earnings (TTM) | NOK 74.76m |
| Revenue (TTM) | NOK 452.29m |
Is VISTN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VISTN income statement (TTM) | |
|---|---|
| Revenue | NOK 452.29m |
| Cost of Revenue | NOK 151.51m |
| Gross Profit | NOK 300.78m |
| Other Expenses | NOK 226.03m |
| Earnings | NOK 74.76m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 24, 2026
| Earnings per share (EPS) | 1.69 |
| Gross Margin | 66.50% |
| Net Profit Margin | 16.53% |
| Debt/Equity Ratio | 0% |
How did VISTN perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/13 23:18 |
| End of Day Share Price | 2026/03/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vistin Pharma ASA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mikkel Nyholt-Smedseng | Carnegie Investment Bank AB |